{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:59:45Z","timestamp":1790110785352,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.prp.2022.154289","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T11:19:46Z","timestamp":1672053586000},"page":"154289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-2088","authenticated-orcid":false,"given":"Stephan","family":"Ledderose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg J.","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.154289_bib1","series-title":"Advances in Oto-rhino-laryngology","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000457937","article-title":"Sinonasal malignant melanoma","author":"Lund","year":"2020"},{"issue":"7","key":"10.1016\/j.prp.2022.154289_bib2","article-title":"Mucosal melanoma: a rare entity and review of the literature","volume":"12","author":"Sohal","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.prp.2022.154289_bib3","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/lary.29820","article-title":"Prognostic value of tumor-infiltrating lymphocytes in sinonasal mucosal melanoma","volume":"132","author":"Ledderose","year":"2022","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/lary.27995","article-title":"Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis","volume":"130","author":"Ganti","year":"2020","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.prp.2022.154289_bib5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw.: JNCCN"},{"key":"10.1016\/j.prp.2022.154289_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers12113131","article-title":"Multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy","volume":"12","author":"Teterycz","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.prp.2022.154289_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/DAD.0000000000002157","article-title":"Sinonasal mucosal melanoma: an update and review of the literature","volume":"44","author":"Salari","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.prp.2022.154289_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105006","article-title":"Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma","volume":"112","author":"Flukes","year":"2021","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.154289_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CMR.0000000000000306","article-title":"Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma","volume":"27","author":"Shoushtari","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2022.154289_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2022.154289_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11912-012-0244-x","article-title":"Mucosal melanoma: pathogenesis, clinical behavior, and management","volume":"14","author":"Postow","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib12","first-page":"116","article-title":"An updated review of mucosal melanoma: survival meta-analysis","volume":"11","author":"Hahn","year":"2019","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.prp.2022.154289_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CMR.0000000000000197","article-title":"Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck","volume":"25","author":"Thierauf","year":"2015","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2022.154289_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2022.151976","article-title":"PD-L1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome","volume":"60","author":"Wang","year":"2022","journal-title":"Ann. Diagn. Pathol."},{"issue":"4","key":"10.1016\/j.prp.2022.154289_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00428-018-02517-1","article-title":"Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology","volume":"474","author":"Giraldo","year":"2019","journal-title":"Virchows Arch.: Int. J. Pathol."},{"issue":"6","key":"10.1016\/j.prp.2022.154289_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2022.154289_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"issue":"6230","key":"10.1016\/j.prp.2022.154289_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.prp.2022.154289_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.03.013","article-title":"The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis","volume":"132","author":"Orhan","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2022.154289_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.prp.2022.154289_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers14163999","article-title":"Identification of the tumor infiltrating lymphocytes (TILs) landscape in pure squamous cell carcinoma of the bladder","volume":"14","author":"Eismann","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2022.154289_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154037","article-title":"Tumor-infiltrating lymphocytes predict survival in \u2265\u2009pT2 urothelial bladder cancer","volume":"237","author":"Ledderose","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"10.1016\/j.prp.2022.154289_bib25","doi-asserted-by":"crossref","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2022.154289_bib26","first-page":"1","article-title":"Prognostic significance of tumor-infiltrating lymphocyte grade in melanoma: a meta-analysis","author":"Sun","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.prp.2022.154289_bib27","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2016"},{"issue":"9","key":"10.1016\/j.prp.2022.154289_bib28","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.18632\/oncotarget.14736","article-title":"Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.prp.2022.154289_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10637-016-0373-4","article-title":"Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry","volume":"34","author":"Cho","year":"2016","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2022.154289_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-017-0552-6","article-title":"Cancer immunotherapy beyond immune checkpoint inhibitors","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2022.154289_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.it.2019.02.002","article-title":"The cellular immunotherapy revolution: arming the immune system for precision therapy","volume":"40","author":"Paucek","year":"2019","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.prp.2022.154289_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"10304","key":"10.1016\/j.prp.2022.154289_bib34","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.prp.2022.154289_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.154289_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2022.154289_bib37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.prp.2022.154289_bib38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2022.154289_bib39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front. Immunol."},{"issue":"101134","key":"10.1016\/j.prp.2022.154289_bib40","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.prp.2022.154289_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.154289_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2022.154289_bib43","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.26511","article-title":"Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma","volume":"118","author":"Jensen","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.prp.2022.154289_bib44","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.154289_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.23543","article-title":"Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression","volume":"123","author":"van Houdt","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2022.154289_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2022.154289_bib47","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","article-title":"Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases","volume":"28","author":"Kakavand","year":"2015","journal-title":"Mod. Pathol.: Off. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"24","key":"10.1016\/j.prp.2022.154289_bib48","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.154289_bib49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2022.154289_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cells8050449","article-title":"The B-side of cancer immunity: the underrated tune","volume":"8","author":"Largeot","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.prp.2022.154289_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.humpath.2016.03.022","article-title":"Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome","volume":"54","author":"Garg","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.154289_bib52","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets Ther."},{"issue":"16","key":"10.1016\/j.prp.2022.154289_bib53","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.prp.2022.154289_bib54","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.prp.2022.154289_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1235107","article-title":"PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome","volume":"5","author":"Obeid","year":"2016","journal-title":"Oncoimmunology"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822005337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822005337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:58:45Z","timestamp":1759733925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822005337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"alternative-id":["S0344033822005337"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.154289","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.154289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154289"}}